Ganitumab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Metastatic SarcomaMetastatic Ewing Sarcoma

12 competitors in Metastatic Sarcoma

#DrugCompanyPhaseTrials

1

Votrient

Novartis

Phase 2

32

Adriamycin

Pfizer

Phase 2

23

Keytruda

Merck & Co.

Phase 1

14

Ganitumab

Amgen

Phase 3

15

Oncovin

Eli Lilly

Preclinical

16

Adriamycin

Pfizer

Preclinical

17

Afinitor

Novartis

Preclinical

18

Camptosar

Pfizer

Preclinical

19

Golytely

Bayer

Preclinical

110

Ifex

BBaxter Healthcare Corporation

Preclinical

1Show 3 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Ewing sarcoma2 trials

Palbociclib + Ganitumab In Ewing Sarcoma

Terminated·—·Phase 2·NCT04129151·10 enrolled

Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

No longer available·JJonsson Comprehensive Cancer Center··NCT03029481

Resistance1 trial

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Completed·NNantBioScience, Inc.·Phase 2·NCT00891930·74 enrolled

Rhabdomyosarcoma1 trial

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT03041701·14 enrolled

Locally Advanced Cancer1 trial

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Completed·Radiation Therapy Oncology Group·Phase 1·NCT01298401·8 enrolled

Metastatic Colorectal Cancer1 trial

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Completed·NNantBioScience, Inc.·Phase 1/2·NCT00788957·177 enrolled

5 more indications

Lymphoma1 trial

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

Completed·Amgen·Phase 1·NCT00562380·64 enrolled

GAN1 trial

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Completed·Amgen·Phase 2·NCT01327612·12 enrolled

Pancreatic Cancer1 trial

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer

Withdrawn·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT01473303

Metastatic Sarcoma1 trial

Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT04199026·20 enrolled

Metastatic Ewing Sarcoma1 trial

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02306161·312 enrolled

Details

Drug Info

Related News